Pulmonary hypertension and gene mutation

Interpretation of pulmonary hypertension from the genetic level

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2100042070

Enrollment

Unknown

Registered

2021-01-13

Start date

2021-01-15

Completion date

Unknown

Last updated

2021-04-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pulmonary hypertation

Interventions

Pulmonary hypertension group:Nil

Healthy control group:Nil

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Pulmonary hypertension group entry criteria: in line with the 2018 Chinese Medical Association Pulmonary Vascular Disease Group "Chinese Pulmonary Hypertension Diagnosis and Treatment Guidelines", diagnostic criteria: at sea level, at rest, right heart catheter measurement of mean pulmonary artery pressure (mPAP ) >= 25 mmHg. Entry criteria for healthy control group: complete routine examinations, no history of chronic diseases such as diabetes, chronic bronchitis, and no history of serious heart and lung diseases, tumors, etc.

Exclusion criteria

Exclusion criteria: Exclude severe infections, ischemic heart disease, malignant tumors, liver and kidney diseases, other major diseases, and mental disorders who cannot cooperate.

Design outcomes

Primary

Measure	Time frame
the allele and genotype frequencies of related gene mutations;the related gene mutation rate;	—

Countries

China

Contacts

Public ContactYiwei Shi

Shanxi Medical University

chinasyw225@163.com+86 13934568990

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026